Lancet oncol: Clinical activity of cabotinib for metastatic urethra cancer in platinum drug resistance

Cabotinib is a polykinase inhibitor of MET, VEGFR, AXL, and RET, and is equally effective in tumor immune microenvironments caused by the suppression of cell reduction from regulatory T cells and myelin sources!----in this study, the researchers assessed the activity of cabotinib for metastatic platinum-recurrence of metastatic epithelial cell carcinomathis study is an open, one-arm, three-queue phase 2 trial that recruits patients over the age of 18 who have been diagnosed with histological path skin cancer or rare types of karnofsky performance scale index of 60 percent, and who have at least one post-platinum chemotherapy (platinum resistance) progressiongive cabotinib 60 mg oral 1/day, 28 days a course of treatment, until the course progresses or the emergence of intolerable toxicitymain endpoint was the objective mitigation rate in Queue 1 (based on the RECIST Assessment) September 28, 2012 - October 20, 2015, with a total of 68 patients (49, 6 and 13, respectively) in Queue 1, 2 and 3all patients receive at least one dose of cabotinibthe median follow-up time for 57 patients who underwent mitigation assessment satwas 61.2 months (IQR 53.8-70.0)one case of total remission and 7 partial remission (objective mitigation rate 19%, 95% CI 9-34) out of 42 patients assessed in queue 1the most common adverse reactions of thewere fatigue (6 cases , 9 percent), hypertension (5 s.7%), proteinuria (4 s.6) and hypophospha (4 s.6))thereno treatment-related deathscabotinib is used in patients with severe pretreatment, platinum-incurable metastatic urethra skin cancer with single drug clinical activity and usually has good toleranceCabotinib has innate and adaptive immune regulatory properties, which provides a theoretical basis for combining it with immunotherapy strategies